Bijgewerkte resultaten KEYNOTE-024-studie

Delen via:
WCLC 2017

Log hier in om volledige toegang te krijgen.

Login of Account maken

 

Bronnen:
Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 17.06.